Latest Commercialisation News

Nexsen Limited has won a $500,000 non-dilutive grant to extend its rapid Group B Streptococcus diagnostic technology into neonatal care, opening a significant new market opportunity.

Temas Resources has appointed Nic Matich as a Non-Executive Director to spearhead Australian investor relations and business development, while CFO David Robinson transitions to a full-time executive role to sharpen financial oversight amid the company’s growth and commercialisation push.

Gold Mountain Limited has reported promising assay results from its Irajuba Prospect in Brazil, revealing significant extensions to rare earth mineralisation and setting the stage for expanded resource drilling.

Cynata Therapeutics has successfully raised $1.2 million through an At-The-Market equity raise, issuing shares at a discount to support its ongoing clinical programs. This capital injection aims to bolster working capital as the company advances its proprietary stem cell therapies.

Codeifai Limited has raised $1.1 million through a share placement to fund the commercialisation of a quantum-secured platform and broaden its AI capabilities into new industrial sectors.

ABx Group has reported exceptional rare earth extraction rates exceeding 80% from column leach tests on bulk samples at its Deep Leads project, suggesting heap leaching could outperform traditional tank methods and accelerate commercial production.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.